Prenetics Appoints Longevity Expert Dr. Darshan Shah to Board, Reinforcing IM8 Growth Strategy

summarizeSummary

Prenetics Global announced a strategic board change, appointing Dr. Darshan Shah, a longevity and health-tech expert, as an independent director, aligning with the company's renewed focus on its IM8 brand.

check_boxKey Events

• Strategic Board Appointment

  Dr. Darshan Shah, a board-certified surgeon and longevity medicine expert, was appointed as an independent director to the Board, effective February 16, 2026. He will also serve on the Audit, Compensation, and Nominating and Corporate Governance Committees.

• Expertise Aligns with Core Strategy

  Dr. Shah's background as founder and CEO of Next Health, a health optimization and longevity center, and his experience in clinical trials and product formulation, directly supports Prenetics' strategic focus on its IM8 health and longevity brand.

• Director Resignation

  Mr. Kong Yiu (Andy) Cheung resigned from the Board, effective February 16, 2026. The company stated his decision was amicable and aligned with the strategic shift to focus on IM8 and discontinue cryptocurrency purchases.

• Reinforces Strategic Pivot

  This board change follows recent divestitures (Insighta, Europa 3PL) and reinforces the company's commitment to concentrating resources and management attention on the global expansion of its IM8 brand.

auto_awesomeAnalysis

Prenetics Global has strategically strengthened its Board of Directors with the appointment of Dr. Darshan Shah, a renowned longevity expert and health-tech CEO. This move directly supports the company's stated pivot to focus entirely on its flagship IM8 health and longevity brand, following recent divestitures of non-core assets. Dr. Shah's extensive clinical and entrepreneurial background in health optimization and product formulation is highly relevant to IM8's global expansion goals. The amicable resignation of Mr. Kong Yiu (Andy) Cheung, attributed to this strategic shift, further underscores the company's commitment to its new direction. This board enhancement, occurring while the stock trades near its 52-week high, signals a focused effort to drive value in its core business.